申请人:Peloton Therapeutics, Inc.
公开号:US20170217891A1
公开(公告)日:2017-08-03
The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
本公开涉及HIF-2α抑制剂及其制备和用于治疗癌症的方法。某些化合物在HIF-2α闪烁近距离法、荧光素酶反应法和VEGF ELISA法中表现出很强的效力,并导致在体外携带786-O异种移植瘤的小鼠中肿瘤大小的减小和回归。